-
Information-Publications
-
Transcription-wide impact by RESCUE-induced off-target single nucleotide variants in mammalian cellDetails -
nCas9 Engineering for Improved Target Interaction Presents an Effective Strategy to Enhance Base EditingDetails -
ATR/Chk1 interacting lncRNA modulates DNA damage response to induce breast cancer chemoresistanceDetails -
Cas9‐orthologue‐mediated cytosine and adenine base editors recognizing NNAAAA PAM sequencesDetails -
mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3IBTK-mediated ubiquitination of eIF4A1 in cancer cellsDetails -
Bioinformatics profiling and experimental validation of 4 differentially-expressed LIM genes in the course of colorectal-adenoma-carcinomaDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands
Back
